Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Reolysin: Began Phase I trial

ONC is 40 percent owned by Synsorb Biotech

Read the full 86 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE